Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Sensitivity, Specificity, and Utility of the Reveal® TP (Syphilis) Antibody POCT to Diagnose Infectious Syphilis in Participants Attending the BCCDC's STI Clinic in Vancouver, BC

NCT05831098 is registered in ClinicalTrials.gov with MedMira Laboratories Inc. as lead sponsor.

NCT NCT05831098
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05831098 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Sensitivity, Specificity, and Utility of the Reveal® TP (Syphilis) Antibody POCT to Diagnose Infectious Syphilis in Participants Attending the BCCDC's STI Clinic in Vancouver, BC
Lead sponsor
MedMira Laboratories Inc.
Phase
Not applicable
Overall status
Completed
Start date
May 12, 2023
Completion date
December 6, 2024
Enrollment
600 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

early syphilis, symptomatic, syphilis, syphilis infection